Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CMPS - COMPASS Pathways Plc - American
Market Cap 408.31M P/E - EPS this Y 0.40% Ern Qtrly Grth -
Income -139.21M Forward P/E -3.50 EPS next Y 4.80% 50D Avg Chg 6.00%
Sales - PEG -0.88 EPS past 5Y - 200D Avg Chg -2.00%
Dividend N/A Price/Book 2.37 EPS next 5Y 3.40% 52W High Chg -58.00%
Recommedations 1.80 Quick Ratio 11.34 Shares Outstanding 68.39M 52W Low Chg 28.00%
Insider Own 24.43% ROA -36.22% Shares Float 41.49M Beta 2.27
Inst Own 42.10% ROE -70.90% Shares Shorted/Prior 5.87M/4.68M Price 8.95
Gross Margin - Profit Margin - Avg. Volume 289,617 Target Price 38.22
Oper. Margin - Earnings Date Oct 31 Volume 309,184 Change 0.00%
Healthcare | Medical Care Facilities | United Kingdom
About COMPASS Pathways Plc - American

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways Plc - American News
12/18/24 Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
11/29/24 Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
11/25/24 Compass Pathways to Participate in December Investor Conferences
11/25/24 COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake
11/14/24 Compass Pathways to participate in Stifel 2024 Healthcare Conference
11/02/24 Compass Pathways cuts 30% of workforce on Phase 3 trial delays
11/01/24 Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
10/31/24 Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript
10/31/24 Compass delays anticipated psilocybin readout, cuts staff
10/31/24 Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates
10/24/24 Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
09/23/24 Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
08/28/24 Compass Pathways to participate in three investor conferences in September
08/25/24 Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
08/19/24 More promise for psilocybin in depression but safety remains a concern
08/06/24 COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference
08/01/24 Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript
08/01/24 Compass Pathways announces second quarter 2024 financial results and business highlights
07/28/24 Weekly Roundup on the Cannabis Sector & Psychedelic Sector
07/24/24 Compass Pathways to announce second quarter financial results on August 1, 2024
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Goldsmith George Jay Director Director Jan 19 Sell 8.17 91,911 750,913 4,169,745 01/23/24
Malievskaia Ekaterina Director Director Jan 19 Sell 8.17 91,911 750,913 4,172,404 01/23/24
Malievskaia Ekaterina Director Director Dec 13 Sell 7.81 8,464 66,104 4,265,867 12/15/23
Goldsmith George Jay Director Director Dec 13 Sell 7.81 8,464 66,104 4,263,209 12/15/23
Malievskaia Ekaterina Chief Innovation Off.. Chief Innovation Officer Feb 01 Sell 12.48 12,744 159,045 4,284,201 03/31/22
Goldsmith George Jay Chief Executive Offi.. Chief Executive Officer Feb 01 Sell 12.48 12,744 159,045 4,268,197 03/31/22
Norton David Y Director Director Mar 29 Sell 12.48 3,384 42,232 20,356 03/31/22
Jenkins Annalisa Director Director Mar 29 Sell 12.48 3,384 42,232 20,356 03/31/22